Hematol Oncol Clin North Am. 2020 Dec;34(6):1133-1144. doi: 10.1016/j.hoc.2020.07.007. Epub 2020 Sep 12.
ABSTRACT
Stem cell transplantation was one of the first proven effective regimens for the management of immunoglobulin light-chain amyloidosis. Criteria for patient selection and the mobilization regimen become important features in ensuring a safe outcome. The technique of stem cell transplantation has evolved considerably in parallel with the development of new chemotherapeutic agents for the management of amyloidosis. Optimal outcomes require both the use of effective novel agent induction and appropriate application of high-dose chemotherapy with subsequent stem cell reconstitution.
PMID:33099429 | PMC:PMC7594100 | DOI:10.1016/j.hoc.2020.07.007